Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trastuzumab - Genentech

Next Previous
Drug Profile

Trastuzumab - Genentech

Alternative Names: Anti-c-erbB-2 monoclonal antibody; Anti-erbB-2- monoclonal antibody; Anti-HER-2 monoclonal antibody; Anti-p185HER-2 monoclonal antibody; HER-2; HER-2 human monoclonal antibody; HER-2 MAb; HER-2 monoclonal antibody; HER-2 murine monoclonal antibody; HER-2/neu MAb; HER-2/neu monoclonal antibody; Herceptin; Herclon; Monoclonal antibody 4D5; R 597; RG597

Latest Information Update: 01 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genentech; Memorial Sloan-Kettering Cancer Center
  • Developer Chugai Pharmaceutical; Dana-Farber Cancer Institute; European Organisation for Research and Treatment of Cancer; FONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA IRCC DI CANDIOLO; Genentech; Jiangsu Hengrui Medicine Co.; Roche; Sanofi; Shanghai Jiaotong University School of Medicine; West German Study Group; Yale University
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Salivary gland cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer; Gastric cancer
  • Registered HER2 positive breast cancer; Salivary gland cancer
  • Phase II Brain metastases; Colorectal cancer; Endometrial cancer
  • Discontinued Non-small cell lung cancer; Pancreatic cancer; Urogenital cancer

Most Recent Events

  • 18 Jan 2024 Efficacy data from a phase II trial in Gastric cancer presented at the 2024 Gastrointestinal Cancers Symposium (ASCO-GCS-2024)
  • 01 Nov 2023 MedSIR completes a phase-II trials in Breast cancer (Neoadjuvant therapy) in Belgium, France, Germany, Italy, Portugal, Spain, United Kingdom (IV) (NCT03161353) (EudraCT2016-002676-27)
  • 20 Oct 2023 Efficacy data from a phase II trial in Breast cancer presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top